Price erosion of key anti diabetes drug Glumetza in the US and muted sales growth in the domestic market due to good and service tax implementation in India resulted in 59 per cent fall in Lupin's profit in first quarter of FY18.
Net profit for the quarter under review of FY18 was Rs 358 crore as against Rs 882 crore in the same period a year ago. Revenue for the quarter too declined 13.4 per cent on a year-on-year basis to Rs 3,869 crore. Along with price erosion and GST disruption, revenue was also impacted due to the strengthening of rupee and headwinds in